MBio Diagnostics, Inc., a Boulder, CO-based developer of rapid, on-the-spot clinical diagnostics and sample testing solutions, raised an additional $6m in Series B financing.
The round was led by new and existing investors, including MBio’s recently announced strategic veterinary partner, Heska Corporation (NASDAQ: HSKA).
The funding supports the refinement of the MBio platform and improvements in manufacturing as the company scales-up to support its commercialization partners.
Led by Chris Myatt, CEO, MBio Diagnostics develops the MBio Array System, a portable multiplex reader that provides lab-quality results in 1 to 20 minutes employing disposable load-and-go cartridges. The system utilizes patented LightDeck® planar waveguide technology that eliminates sample prep and can be designed to detect all key analytes including: proteins, cells, nucleic acids, and small molecules.
The company aims to bring its platform to providers and users of clinical and analytical testing services in all market segments including: medical, veterinary, environmental, food, agricultural and military.